Glutathione side effects get described in soft language: a little bloating, maybe a rash. That language comes from studies of capsules. The clear vials sold in wellness clinics are a different product, and the federal record on those vials reads badly.
The short answer, in one sentence: injected glutathione has no FDA approval in the United States, and the serious reactions in the government’s file trace to a contaminated ingredient rather than to the peptide itself.
The cluster started in July 2026. The Texas Department of State Health Services notified the Centers for Disease Control and Prevention about a group of patients who became sick after receiving intravenous glutathione at an outpatient wellness clinic. By the CDC’s update of September 11, 2026, the reports covered more than 25 people sick across at least four states: Texas, Washington, Florida and New York (CDC, updated September 11, 2026).
Three of them reached a hospital. All three had the intravenous form. One became critically ill, needed intensive care, and got treatment for shock and for abnormal blood clotting.
Glutathione Side Effects: What the Federal Record States
The CDC lists what it is tracking: fever and chills, body aches, headache, nausea, dizziness and low blood pressure. Those are not the mild, slow complaints normally attached to this molecule. They carry the signature of endotoxin, a fragment of bacterial cell wall that survives a badly controlled powder and drives a fast inflammatory reaction.
FDA’s own notice, current as of August 27, 2026, puts the count higher at “at least 30 patients” and adds a fact the CDC summary leaves out: the glutathione behind those reactions came through one supply chain. Different compounding pharmacies prepared the injections, and each of them bought its glutathione, lot number 229536, from Medisca Inc. in Plattsburgh, New York. FDA describes the material as “labeled as dietary supplement grade, which is not an appropriate ingredient to make injectable drugs” (FDA, August 27, 2026).
Two agencies, two counts, one story. The gap between 25 and 30 is not a contradiction. It is what an open investigation looks like while it is still counting.
The Reaction: Fever, Chills, and an ICU Bed
Endotoxin needs no large dose and no long infusion. The 2019 file shows the speed. FDA received an adverse event report on January 14, 2019, describing seven patients at an outpatient clinic who each received 7 millilitres, or 1,400 milligrams, of compounded L-glutathione by injection on January 9. A second report arrived on February 4, 2019: one patient took 12 millilitres, 2,400 milligrams, in an infusion on October 17, 2018, and within hours had sudden chills, fever and shaking, then a hospital admission for a suspected bloodstream infection (FDA, 2019).
The powder those pharmacies used carried the words “Caution: Dietary Supplement” on its label. FDA tested the material and confirmed endotoxin levels higher than the dose could account for.
Seven years later the pattern returns with a different supplier and a larger count. One patient in the 2026 cluster needed intensive care for shock and for abnormal clotting. That is a long way from a blush and a bit of nausea, and it is the part of this record a clinic front desk will not mention.
One Lot Number, Four States
FDA’s August notice names the thread that ties the cases together: lot 229536 from Medisca. The agency reports that Medisca told FDA on August 20, 2026 that it had written to its US customers warning them not to put its dietary supplement grade glutathione into injectable drugs.
Recalls followed the testing. By September 11, 2026, the CDC counted at least three Texas pharmacies pulling compounded injectable glutathione over high endotoxin levels. One of them, Greenwich Rx of Tomball, Texas, a 503A compounding pharmacy, published a nationwide recall on October 1, 2026 covering ten lots of glutathione injection at 200 milligrams per millilitre in 10 millilitre multidose vials, dispensed for subcutaneous injection. The stated reason on the notice: potential elevated endotoxin levels (FDA recall notice, October 1, 2026).
Ten lots is not a rounding error. It is a batch record.
Oral Glutathione Side Effects: What the Trials Recorded
Swallowed glutathione is a separate exposure, and two randomized trials from Bangkok give the numbers.
Arjinpathana and Asawanonda gave 60 healthy medical students either 500 milligrams a day of glutathione or placebo for four weeks. Melanin index fell at all six measured sites in the glutathione group, and the drop beat placebo at two of them: the right side of the face (p = 0.021) and the sun-exposed left forearm (p = 0.036). Both arms tolerated the capsules well. The authors closed with a caution that matters more than the result: “long-term safety has not been established” (J Dermatolog Treat, April 2012).
Weschawalit and colleagues ran 60 women for twelve weeks at 250 milligrams a day of reduced or oxidized glutathione against placebo. Adverse events in the two treatment arms combined came to five of 38 patients, or 13.15 percent: itching, faint redness, small transient red spots, tiredness. The placebo group logged four events in 19, a higher rate than the drug arms. Two participants stopped early because their liver enzymes rose, and the paper reports those results returning to normal within a few weeks (Clin Cosmet Investig Dermatol, April 27, 2017).
Read those two trials for what they are: evidence about a capsule swallowed at home. Neither one tested an injection. Neither one drew from a compounding pharmacy’s vial.
Why the Powder Carries the Risk
Glutathione is a tripeptide, three amino acids joined in a chain, and the body makes its own. That is the fact clinics lean on when they call the shot harmless.
The harm in this record sits upstream of the molecule, in the grade of the raw material and the sterility of the room it entered. Ingredients sold for dietary supplements are not manufactured to sterile injectable standards. They can carry endotoxin, and endotoxin survives the mixing process. CDC’s instruction to clinics is blunt: confirm with the compounding pharmacy that the ingredient in any injectable glutathione is appropriate for the route, and do not administer product whose ingredient grade cannot be verified.
That instruction lands on the clinic, which means it lands on you as a question at the counter.
Injectable Glutathione: No Approval and No Label Dose
CDC states plainly that there are no FDA-approved glutathione products in the United States. That one sentence changes what a clinic can tell you.
An approved drug arrives with a label: a dose, a known reaction list, a warning section, a manufacturer who answers for it. A compounded injection arrives with a pharmacy’s own paperwork. A clinic that quotes you a dose is quoting a number with no federal counterpart behind it. Our guide to reading a 503A pharmacy’s paperwork covers the questions that replace a label.
Absent a label, the published evidence on the injected form is thin. Sarkar and colleagues reviewed the literature in 2024 and located one placebo-controlled study of intravenous glutathione: 6 of 16 patients, or 37.5 percent, against 3 of 16, or 18.7 percent, at p = 0.054, which misses the usual threshold for significance. Their verdict is unusually direct for a review: “IV glutathione is contraindicated due to lack of efficacy and side effects.” They rated topical and oral forms as having minimal and substantial adverse effects respectively, and noted the benefit fades once treatment stops (PubMed 39444151, 2024).
So the injected form carries the thinnest evidence and the worst safety file of the three routes. That is the opposite of how it gets sold.
What to Ask Before You Accept a Glutathione Injection
- Ask which pharmacy compounded the vial, and write the name down.
- Ask which grade of glutathione went into it, and whether that grade was manufactured for injection.
- Ask to see the certificate of analysis for the lot, including the endotoxin result.
- Ask whether that pharmacy has recalled any glutathione in the past year.
- Ask what the clinic does if you develop fever, chills or dizziness in the hours after a shot.
We built a printable list of questions for a peptide clinic consultation for the same reason. A clinic that cannot answer the first four has not checked its supply chain.
If you already had a reaction, CDC asks you to report it to FDA MedWatch and to your state or local health department. A report is what turns a bad afternoon into a data point the next patient can find.
Frequently asked questions
What are the side effects of glutathione injections?
The federal record from the 2026 cluster lists fever and chills, body aches, headache, nausea, dizziness and low blood pressure. CDC says reactions can be severe and may need emergency care, and that at least three patients were hospitalized (CDC, September 11, 2026).
Why did people get sick from glutathione injections in 2026?
FDA traced the vials to one supply chain: glutathione lot 229536 from Medisca, labeled dietary supplement grade, which is not suitable for making injectable drugs. Endotoxin from that material is the likely cause of the reactions, not glutathione itself.
Is injectable glutathione FDA approved?
No. CDC states that there are no FDA-approved glutathione products in the United States, which means injectable glutathione is a compounded drug with no approved label, no approved dose and no manufacturer-held safety database.
What are the side effects of oral glutathione?
In a 12-week randomized trial of 60 women, treatment arms reported itching, faint redness, small transient red spots and tiredness in 13.15 percent of patients, a lower rate than placebo. Two participants had reversible liver enzyme rises (Clin Cosmet Investig Dermatol, 2017).
Do glutathione side effects go away?
The skin reactions in the oral trial resolved during the study, and the two liver enzyme rises normalized within a few weeks. Endotoxin reactions are different: CDC describes them as sudden and potentially severe, so they need assessment rather than waiting.
Is glutathione a peptide?
Yes. Glutathione is a tripeptide built from three amino acids, and the body produces it. Being a natural peptide does not make a compounded injectable version safe, and it does not give the injection an FDA approval.
What should you do if you feel unwell after a glutathione injection?
Stop and get assessed. CDC advises anyone with fever, chills, severe body aches, nausea, vomiting, dizziness or injection-site pain, swelling or redness to contact a clinician promptly, and to seek emergency care for breathing difficulty, fainting or signs of shock.
Sources:
- CDC, Adverse Events Linked to Injectable Glutathione Compounded with Dietary Supplement Grade Ingredient: Current Situation, updated September 11, 2026.
- FDA, FDA reminds compounders not to use dietary supplement grade glutathione for injectables, August 27, 2026.
- FDA, Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels, October 1, 2026.
- FDA, FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables, 2019.
- Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat, April 2012.
- Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol, April 27, 2017.
- Sarkar R, Yadav V, Yadav T, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review, 2024.
This article is information, not medical advice. Injectable glutathione is a compounded drug with no FDA approval in the United States, and suitability, dosing and monitoring belong to a licensed prescriber who knows your history. A reaction after an injection should go to a clinician and to FDA MedWatch. Our map of the FDA safety record on peptides tracks what the agency has flagged.